Among 38 patients who underwent PD-L1 immunohistochemical testing after developing EGFR-TKI resistance, we also explored changes in PD-L1 expression in tumor cells between before receiving EGFR-TKI treatment and the development of drug resistance. Here, EGFR is linked to neoplasm.